Alnylam Pharmaceuticals, Inc. (0HD2.L)
USD 232.29
(0.02%)
USD 232.29
(0.02%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.51 Billion USD | 74.75% |
| 2022 | 868.6 Million USD | 23.36% |
| 2021 | 704.14 Million USD | 69.75% |
| 2020 | 414.8 Million USD | 113.06% |
| 2019 | 194.68 Million USD | 192.01% |
| 2018 | 66.67 Million USD | -12.9% |
| 2017 | 76.54 Million USD | 62.31% |
| 2016 | 47.15 Million USD | 14.75% |
| 2015 | 41.09 Million USD | -18.72% |
| 2014 | 50.56 Million USD | 7.2% |
| 2013 | 47.16 Million USD | -29.31% |
| 2012 | 66.72 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 415.01 Million USD | -29.8% |
| 2024 Q1 | 428.35 Million USD | 21.05% |
| 2024 Q2 | 591.15 Million USD | 38.0% |
| 2023 Q3 | 666.22 Million USD | 185.46% |
| 2023 Q4 | 353.86 Million USD | -46.89% |
| 2023 FY | 1.51 Billion USD | 74.75% |
| 2023 Q1 | 264.42 Million USD | -6.82% |
| 2023 Q2 | 233.38 Million USD | -11.74% |
| 2022 Q3 | 223.18 Million USD | 21.29% |
| 2022 Q2 | 184.01 Million USD | 3.59% |
| 2022 FY | 868.6 Million USD | 23.36% |
| 2022 Q1 | 177.63 Million USD | -19.58% |
| 2022 Q4 | 283.76 Million USD | 27.14% |
| 2021 Q2 | 181.79 Million USD | 24.09% |
| 2021 Q4 | 220.87 Million USD | 42.53% |
| 2021 FY | 704.14 Million USD | 69.75% |
| 2021 Q1 | 146.5 Million USD | 4.25% |
| 2021 Q3 | 154.97 Million USD | -14.76% |
| 2020 Q4 | 140.53 Million USD | 35.06% |
| 2020 FY | 414.8 Million USD | 113.06% |
| 2020 Q3 | 104.05 Million USD | 23.83% |
| 2020 Q2 | 84.03 Million USD | -2.48% |
| 2020 Q1 | 86.17 Million USD | 44.82% |
| 2019 Q1 | 29.94 Million USD | 54.62% |
| 2019 FY | 194.68 Million USD | 192.01% |
| 2019 Q4 | 59.5 Million USD | -8.24% |
| 2019 Q3 | 64.84 Million USD | 60.56% |
| 2019 Q2 | 40.38 Million USD | 34.86% |
| 2018 Q2 | 29.9 Million USD | 36.57% |
| 2018 Q1 | 21.89 Million USD | -42.26% |
| 2018 FY | 66.67 Million USD | -12.9% |
| 2018 Q4 | 19.36 Million USD | 902.48% |
| 2018 Q3 | 1.93 Million USD | -93.54% |
| 2017 Q4 | 37.92 Million USD | 121.83% |
| 2017 FY | 76.54 Million USD | 62.31% |
| 2017 Q3 | 17.09 Million USD | 7.31% |
| 2017 Q2 | 15.93 Million USD | -15.97% |
| 2017 Q1 | 18.96 Million USD | 8.63% |
| 2016 Q1 | 7.34 Million USD | -2.73% |
| 2016 Q2 | 8.7 Million USD | 18.57% |
| 2016 Q4 | 17.45 Million USD | 27.86% |
| 2016 Q3 | 13.65 Million USD | 56.75% |
| 2016 FY | 47.15 Million USD | 14.75% |
| 2015 Q1 | 18.53 Million USD | -22.82% |
| 2015 FY | 41.09 Million USD | -18.72% |
| 2015 Q4 | 7.55 Million USD | 19.4% |
| 2015 Q3 | 6.32 Million USD | -27.18% |
| 2015 Q2 | 8.68 Million USD | -53.15% |
| 2014 Q4 | 24.01 Million USD | 118.91% |
| 2014 Q3 | 10.97 Million USD | 50.4% |
| 2014 Q2 | 7.29 Million USD | -11.84% |
| 2014 Q1 | 8.27 Million USD | -23.71% |
| 2014 FY | 50.56 Million USD | 7.2% |
| 2013 FY | 47.16 Million USD | -29.31% |
| 2013 Q4 | 10.84 Million USD | 20.64% |
| 2013 Q1 | 18.64 Million USD | 119.45% |
| 2013 Q2 | 8.68 Million USD | -53.4% |
| 2013 Q3 | 8.99 Million USD | 3.5% |
| 2012 FY | 66.72 Million USD | 0.0% |
| 2012 Q4 | 8.49 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| uniQure N.V. | 2.21 Million USD | -68427.585% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -502511.258% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 1881.222% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 56.194% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | -8664.282% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | -319.271% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 485047.604% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | -520.723% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 20.295% |
| bluebird bio, Inc. | -4.03 Million USD | 37764.665% |
| Blueprint Medicines Corporation | 236.58 Million USD | -541.584% |
| Cara Therapeutics, Inc. | 14.79 Million USD | -10160.146% |
| Imunon, Inc. | -720 Thousand USD | 210916.036% |
| Adicet Bio, Inc. | -6.09 Million USD | 24991.538% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | -218.955% |
| Dynavax Technologies Corporation | 182.11 Million USD | -733.467% |
| Editas Medicine, Inc. | -99.52 Million USD | 1625.084% |
| Emergent BioSolutions Inc. | 343.9 Million USD | -341.374% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -1977.389% |
| Exelixis, Inc. | 1.75 Billion USD | 13.642% |
| FibroGen, Inc. | 128.9 Million USD | -1077.532% |
| Geron Corporation | -123.5 Million USD | 1329.028% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | -138.327% |
| Heron Therapeutics, Inc. | 10.04 Million USD | -15015.375% |
| Illumina, Inc. | 2.74 Billion USD | 44.683% |
| Incyte Corporation | 3.44 Billion USD | 55.884% |
| Insmed Incorporated | 239.63 Million USD | -533.416% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 480.619% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | -94.972% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 15967.51% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 71.027% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 501052.475% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 30.021% |
| Evolus, Inc. | 140.52 Million USD | -980.146% |
| Myriad Genetics, Inc. | 476.4 Million USD | -218.616% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 17.837% |
| OPKO Health, Inc. | 318.12 Million USD | -377.132% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | -38.874% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | -189.816% |
| Verastem, Inc. | -62 Thousand USD | 2448303.226% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 94.277% |
| Waters Corporation | 1.76 Billion USD | 13.815% |
| Zoetis Inc. | 5.83 Billion USD | 73.982% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 82.365% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 90.03% |
| Biogen Inc. | 7.3 Billion USD | 79.213% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 3448.894% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 86.569% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 4970.067% |
| Homology Medicines, Inc. | -7.22 Million USD | 21097.178% |
| Nektar Therapeutics | 53.47 Million USD | -2738.337% |
| TG Therapeutics, Inc. | 219.1 Million USD | -592.757% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 519923.973% |
| Perrigo Company plc | 1.68 Billion USD | 9.671% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 7805.396% |